Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Vaughn

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Journal of Clinical Microbiology|March 7, 2006
Evidence that rodents are a reservoir of hepatitis E virus for humans in NepalJunkun He, Bruce L Innis, Mrigendra P Shrestha, et al.
The Journal of Infectious Diseases|April 28, 2009
TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic ThaisSasijit Vejbaesya, Panpimon Luangtrakool, Komon Luangtrakool, et al.
Journal of Clinical Microbiology|November 28, 2002
Evidence that rodents are a reservoir of hepatitis E virus for humans in NepalJunkun He, Bruce L Innis, Mrigendra P Shrestha, et al.
Lancet (London, England)|March 19, 2003
Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trialTom Solomon, Nguyen Minh Dung, Bridget Wills, et al.
The Journal of Infectious Diseases|December 11, 2012
Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccinesWellington Sun, Kenneth H Eckels, J Robert Putnak, et al.
BMC Infectious Diseases|September 18, 2013
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trialsOdile Launay, Xavier Duval, Serge Fitoussi, et al.
The Lancet. Global Health|March 28, 2025
A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systemsMarco Cavaleri, Claudiosvam M Alves de Sousa, Adam Hacker, et al.
Vaccine|August 13, 2013
A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU)Robert V Gibbons, Ananda Nisalak, In-Kyu Yoon, et al.
The Pediatric Infectious Disease Journal|July 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging StudyJoon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, et al.
Plos Neglected Tropical Diseases|December 28, 2007
A comparative study of leptospirosis and dengue in Thai childrenDaniel H Libraty, Khin S A Myint, Clinton K Murray, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Journal of Clinical Microbiology|March 7, 2006
Evidence that rodents are a reservoir of hepatitis E virus for humans in NepalJunkun He, Bruce L Innis, Mrigendra P Shrestha, et al.
The Journal of Infectious Diseases|April 28, 2009
TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic ThaisSasijit Vejbaesya, Panpimon Luangtrakool, Komon Luangtrakool, et al.
Journal of Clinical Microbiology|November 28, 2002
Evidence that rodents are a reservoir of hepatitis E virus for humans in NepalJunkun He, Bruce L Innis, Mrigendra P Shrestha, et al.
Lancet (London, England)|March 19, 2003
Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trialTom Solomon, Nguyen Minh Dung, Bridget Wills, et al.
The Journal of Infectious Diseases|December 11, 2012
Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccinesWellington Sun, Kenneth H Eckels, J Robert Putnak, et al.
BMC Infectious Diseases|September 18, 2013
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trialsOdile Launay, Xavier Duval, Serge Fitoussi, et al.
The Lancet. Global Health|March 28, 2025
A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systemsMarco Cavaleri, Claudiosvam M Alves de Sousa, Adam Hacker, et al.
Vaccine|August 13, 2013
A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU)Robert V Gibbons, Ananda Nisalak, In-Kyu Yoon, et al.
The Pediatric Infectious Disease Journal|July 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging StudyJoon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, et al.
Plos Neglected Tropical Diseases|December 28, 2007
A comparative study of leptospirosis and dengue in Thai childrenDaniel H Libraty, Khin S A Myint, Clinton K Murray, et al.
Pageof 10